NCT06634056 - Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2031

Conditions

Non-Small Cell Lung CancerRadiation Induced Lung Injury (RILI)

Interventions

DRUG

Pentoxifylline

Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.

OTHER

Placebo

One placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.

OTHER

α-Tocopherol

Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.

Trial Locations (1)

M5G 2C1

University Health Network - Princess Margaret Cancer Centre, Toronto